Abstract 3266
Background
Colorectal liver metastases (CLM) display a high heterogeneity, responsible for a wide array of clinical presentations and responsiveness to treatments. In the era of precision medicine, there is a critical need of reliable prognostic markers to improve patient stratification and, for their predominance in metastatic tissues, tumor-associated macrophages (TAMs) emerge as promising candidates. The aim of this study was to test the presence of discrete TAM populations in CLM patients on the basis of morphology, and to test the impact of TAMs morphology on recurrence-free survival (RFS).
Methods
NCT038888638 is a single-center study conducted in a tertiary-referral university hospital that examined a cohort of patients with CLMs that underwent hepatectomy between 2005 and 2017. TAMs cell density, cell area and cell perimeter were systematically quantified in 3 non-contiguous and non-overlapping areas of CLM sections by means of immuno-reactive area of CD163+ macrophages. The association of TAMs metrics and RFS was tested by using receiver operating characteristics (ROC) curves, multivariate Cox regression analysis and survival analysis.
Results
A cohort of 101 CLM patients resected between 2005 and 2017 was considered. Among density (AUC=0.555; 95%CI=0.410-0.701; P = 0.449), perimeter (AUC=0.526; 95%CI=0.383-0.671; P = 0.708) and area (AUC=0.791; 95%CI=0.572-0.841; P = 0.006) ofCD163+ TAMs, only the latter was significantly associated with differences in survival time. Small and large TAMs, as defined by using the best cutoff value extrapolated from the ROC curve (area: 60.39 μm2; Se = 0.79; Sp = 0.44), were clearly associated with significantly different 5-year RFS rates of 27.8% and 0.2% respectively (P < 0.001). At the multivariate analysis, including TAMs area and several prognostic factors, only TAMs area was found to be independently statistically associated with RFS (HR = 3.41; 95%CI=1.13-5.43; P = 0.001).
Conclusions
Macrophage morphology is critically associated with prognosis of CLM patients. The results reported here support that accurate quantitative morphometric characterization of TAMs can serve as an easily quantifiable correlate of functional diversity with prognostic significance.
Clinical trial identification
NCT038888638.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract